Design Therapeutics, INC 10-Q quarterly reports

Design Therapeutics, Inc. (DSGN) filed its Form 10-Q for the quarter ended June 30, 2026, detailing advancements in its GeneTAC platform, particularly for Friedreich's Ataxia, while reporting continued net losses.

Design Therapeutics, Inc. reported its first quarter 2026 financial results, highlighting progress in its GeneTAC molecule development for rare diseases and a net loss of $17.6 million.

Design Therapeutics, a clinical-stage biopharmaceutical company, reported increased net losses for Q3 2025 while progressing its GeneTAC molecule pipeline, despite an FDA clinical hold on its lead FA program in the U.S.

Design Therapeutics reported increased net losses in Q2 2025, driven by higher R&D expenses, and disclosed an FDA clinical hold on its lead FA program, DT-216P2, for the U.S. starting dose.

Design Therapeutics reports a net loss for Q1 2025 and provides updates on its GeneTAC molecule development programs targeting inherited nucleotide repeat expansion diseases.

Design Therapeutics reported its third quarter 2024 financial results and provided updates on its clinical development programs, including a revised timeline for its Friedreich ataxia program.

Design Therapeutics reports a net loss of $22.9 million for the six months ended June 30, 2024, while advancing its GeneTAC platform and clinical programs.

Design Therapeutics reported a net loss of $11.1 million for the first quarter of 2024, while advancing its GeneTAC platform and preparing for clinical trials of DT-216P2 in Friedreich ataxia.